Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? – a pharmacoeconomic study. Headache Medicine, [S. l.], v. 15, n. Supplement, p. 98, 2024. Disponível em: https://headachemedicine.com.br/hm/article/view/1230. Acesso em: 22 jan. 2026.